|
Summary Information: Ampio Pharmaceuticals Inc. AMEX:AMPE |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK). Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need. Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035. In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).
__The following are links to various summary and news pages for __Ampio Pharmaceuticals Inc. [ AMPE ]. __Note: Some Links might not have information for the company. |
|